Allspring Global Investments’s MacroGenics MGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$130K Buy
+28,172
New +$107K ﹤0.01% 1691
2024
Q2
– Sell
-12,701
Closed -$187K – 2477
2024
Q1
$187K Sell
12,701
-28,133
-69% -$425K ﹤0.01% 1720
2023
Q4
$393K Buy
40,834
+15,994
+64% +$111K ﹤0.01% 1554
2023
Q3
$116K Sell
24,840
-37,868
-60% -$189K ﹤0.01% 1942
2023
Q2
$335K Buy
62,708
+46,218
+280% +$285K ﹤0.01% 1660
2023
Q1
$118K Buy
16,490
+7,209
+78% +$43.4K ﹤0.01% 1984
2022
Q4
$62.3K Buy
9,281
+6,451
+228% +$35.4K ﹤0.01% 2260
2022
Q3
$9K Buy
+2,830
New +$10.8K ﹤0.01% 2737
2022
Q2
– Sell
-27,106
Closed -$238K – 2832
2022
Q1
$238K Buy
27,106
+788
+3% +$8.7K ﹤0.01% 2513
2021
Q4
$422K Buy
+26,318
New +$495K ﹤0.01% 2365

Other funds holding MGNX

Allspring Global Investments's MGNX Position: Q2 2026 in Review

Allspring Global Investments opened a new position in MacroGenics (MGNX) in Q2 2026: 28,172 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #1691 among its holdings. This is a return to the name: Allspring Global Investments previously reported a position in MGNX as recently as Q1 2024.

Allspring Global Investments first reported a position in MGNX in Q4 2021 and has held it in 10 quarters since. The position peaked at $422K in Q4 2021. 122 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

  • Allspring Global Investments held 28,172 shares of MacroGenics worth $130K as of Q2 2026.
  • MacroGenics was a new Allspring Global Investments position in Q2 2026.
  • MacroGenics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1691 holding.
  • Allspring Global Investments first reported a position in MacroGenics in Q4 2021 and has held it in 10 quarters since.
  • Allspring Global Investments's MacroGenics position peaked at $422K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.